(News Bulletin 247) – Oddo BHF confirms its outperformance rating on the OSE Immunotherapeutics share with an unchanged price target of 7 euros.
The analyst reports that the DSMB (Data Monitoring and Monitoring Board) of the CoTikiS phase 2 evaluating lusvertikimab in ulcerative colitis (UC) has decided in favor of continuing the study until its completion.
“We are expecting the results of the induction part (10 weeks of treatment) in December 2023 as well as the maintenance results after 6 months of treatment at the end of S1 2024, two major catalysts for the company”, indicates Oddo BHF.
According to the broker, the main downside to its short-term investment thesis remains the limited financial visibility today in Q2 2024e, despite the establishment of an equity line.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
